Qiagen - QGEN Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" QGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QGEN, but not buy additional shares or sell existing shares.
View QGEN analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12 month price objectives for Qiagen's shares. Their QGEN share price forecasts range from $52.00 to $60.00. On average, they predict the company's share price to reach $55.53 in the next year. This suggests a possible upside of 21.1% from the stock's current price.
View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts.

Qiagen's stock was trading at $49.87 at the start of the year. Since then, QGEN shares have decreased by 8.1% and is now trading at $45.84.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our QGEN earnings forecast.

Qiagen (NYSE:QGEN) released its quarterly earnings data on Tuesday, February, 7th. The company reported $0.53 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.06. The company earned $531 million during the quarter, compared to analyst estimates of $486.93 million. Qiagen had a trailing twelve-month return on equity of 16.45% and a net margin of 19.76%. Qiagen's quarterly revenue was down 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.74 EPS.

ETFs with the largest weight of Qiagen (NYSE:QGEN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), VanEck Biotech ETF (BBH), Newday Ocean Health ETF (AHOY), Franklin Genomic Advancements ETF (HELX) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

Qiagen issued an update on its FY 2023 earnings guidance on Tuesday, February, 7th. The company provided EPS guidance of $2.10- for the period, compared to the consensus estimate of $2.12. The company issued revenue guidance of $2.05B-, compared to the consensus revenue estimate of $2.07 billion.

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Qiagen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Amundi (3.27%), Norges Bank (2.53%), Pendal Group Ltd (1.89%), Arrowstreet Capital Limited Partnership (1.63%), Morgan Stanley (1.28%) and Marshall Wace LLP (0.97%).

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QGEN stock can currently be purchased for approximately $45.84.

Qiagen (NYSE:QGEN) has a market capitalization of $10.44 billion and generates $2.14 billion in revenue each year. The company earns $423.21 million in net income (profit) each year or $1.84 on an earnings per share basis.

The company employs 6,000 workers across the globe.

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658.